Despite a wide range of therapies for patients with type 2 diabetes and obesity,
only intensive dietary and lifestyle interventions or bariatric surgery provide substantial weight
loss to reduce insulin resistance and improve glycemic control. Improvements in glucose
metabolism after surgery precede weight loss and are associated with alterations in circulating
levels of gut hormones, including oxyntomodulin and glucagon-like peptide-1 (GLP-1).
MEDI0382, a single peptide with GLP-1 and glucagon (GCG) receptor dual-agonist activity, is
designed to mimic the effects of oxyntomodulin. Results from preclinical studies and the firsttime-
in-humans (FTIH) study are presented.